Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Dec;24(8):722-31.
doi: 10.1111/ajad.12292. Epub 2015 Sep 21.

The impact of addiction medications on treatment outcomes for persons with co-occurring PTSD and opioid use disorders

Elizabeth C Saunders  1   2 , Mark P McGovern  3   4 , Chantal Lambert-Harris  3 , Andrea Meier  3 , Bethany McLeman  1 , Haiyi Xie  4
Affiliations
Randomized Controlled Trial

The impact of addiction medications on treatment outcomes for persons with co-occurring PTSD and opioid use disorders

Elizabeth C Saunders et al. Am J Addict. 2015 Dec.

Abstract

Background and objectives: Previous research has been inconclusive about whether adding psychosocial treatment to medication assisted treatment (MAT) improves outcomes for patients with co-occurring psychiatric and opioid use disorders. This study evaluated the impact of MAT and psychosocial therapies on treatment outcomes for patients with co-occurring opioid use disorders and PTSD.

Methods: Patients meeting criteria for PTSD and substance use disorders were randomly assigned to one of three treatment conditions: Standard Care (SC) alone, Integrated Cognitive Behavioral Therapy (ICBT) plus SC, or Individual Addiction Counseling (IAC) plus SC. Substance use and psychiatric symptoms were assessed at baseline and 6 months. Only patients with opioid use disorders were included in the present analyses (n = 126). Two-way ANOVAS and logistic regression analyses were used to examine associations between treatment conditions and MAT, for substance use and psychiatric outcomes.

Results: MAT patients receiving ICBT had significantly decreased odds of a positive urine drug screen, compared to non-MAT patients receiving SC alone (OR = .07, 95% CI = .01, .81, p = .03). For PTSD symptoms, a significant MAT by psychosocial treatment condition interaction demonstrated that MAT patients had comparable declines in PTSD symptoms regardless of psychosocial treatment type (F(2, 88) = 4.74, p = .011). Non-MAT patients in ICBT had significantly larger reductions in PTSD.

Conclusions and scientific significance: For patients with co-occurring opioid use disorders and PTSD, MAT plus ICBT is associated with more significant improvement in substance use. For non-MAT patients, ICBT is most beneficial for PTSD symptoms.

Keywords: co-occurring disorders; integrated treatment; medication-assisted treatment; opioid dependence; posttraumatic stress disorder.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.

Figures

FIG. 1
FIG. 1
Predicted probabilities and 95% confidence intervals of positive drug toxicology screen by medication assisted treatment (MAT) prescription status and treatment type. (MAT, medication assisted treatment; ICBT, integrated cognitive behavioral therapy; IAC, individual addiction counseling; SC, standard care.)
FIG. 2
FIG. 2
Changes in clinician administered PTSD Scale (CAPS) total scores from baseline to 6 months by medication assisted treatment (MAT) prescription and psychosocial treatment type. (MAT, medication assisted treatment; ICBT, integrated cognitive behavioral therapy; IAC, individual addiction counseling; SC, standard care.)
See this image and copyright information in PMC

References

    1. Substance Abuse and Mental Health Services Administration (SAMHSA) Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Administration (SAMHSA); 2013.
    1. Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:Cd002207. - PMC - PubMed
    1. Volkow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies-Tackling the opioid-overdose epidemic. N E J Med. 2014;370:2063–2066. - PubMed
    1. Substance Abuse and Mental Health Services Administration. About one-third of substance abuse treatment admissions had a psychiatric problem. Rockville, MD: 2014.
    1. Mills KL, Teesson M, Ross J, et al. The costs and outcomes of treatment for opioid dependence associated with posttraumatic stress disorder. Psychiatr Serv. 2005;56:940–945. - PubMed

Publication types

Substances